nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

28.06.2018 | Review

Genetic approach towards a vaccine against malaria

verfasst von: Jose Antonio Garrido-Cardenas, Concepción Mesa-Valle, Francisco Manzano-Agugliaro

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Malaria is a major concern for international health authorities. Millions of people contract it every year in the world due to a parasite of the Plasmodium genus. Due to the complexity of the parasite biology and genetics, there is currently no vaccine against the disease. However, due to the great resistance both to the medicines and to the insecticides used to combat the disease, it has become essential to obtain a vaccine as the necessary tool to prevent transmission and eliminate the disease. The bibliometric data indicate that interest in vaccines has been growing steadily since the 1980s. But nowadays, a powerful tool is used: the Plasmodium genome. This allows us to improve the fight against the disease. Knowing the sequences of the genes that favor the appearance of drug resistance, or those that encode for proteins with greater antigenic response, is a tool that can become fundamental. This article reviews the state of the art on vaccines and genetics, in the fight against malaria, and analyzes the fixed photo that the worldwide research on the disease poses.

Barber BE, Rajahram GS, Grigg MJ, William T, Anstey NM (2017) World malaria report: time to acknowledge Plasmodium knowlesi malaria. Malar J 16:135. https://doi.org/10.1186/s12936-017-1787-y CrossRefPubMedPubMedCentral

Naing C, Whittaker MA, Nyunt Wai V, Mak JW (2014) Is Plasmodium vivax malaria a severe malaria?: A systematic review and meta-analysis. PLoS Negl Trop Dis 8:e3071. https://doi.org/10.1371/journal.pntd.0003071 CrossRefPubMedPubMedCentral

Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64:97–106. https://doi.org/10.1179/2047772413Z.000000000179 CrossRefPubMed

Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J et al (2017) malERA: an updated research agenda for malaria elimination and eradication. PLoS Med. 14:e1002456. https://doi.org/10.1371/journal.pmed.1002456 CrossRefPubMedPubMedCentral

Rieckmann KH, Beaudoin RL, Cassells JS, Sell KW (1979) Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 57:261–265PubMedPubMedCentral

Baird JK, Baird JK (1998) Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 92:367–390CrossRefPubMed

Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C (1999) Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 5:340–343. https://doi.org/10.1038/6560 CrossRefPubMed

Webster D, Hill AVS (2003) Progress with new malaria vaccines. Bull World Health Organ 81:902–909. https://doi.org/10.1590/S0042-96862003001200009 CrossRefPubMed

Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P et al (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45:297–308CrossRefPubMed

10.

Conway DJ (2015) Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet 31:97–107. https://doi.org/10.1016/j.tig.2014.12.005 CrossRefPubMedPubMedCentral

11.

Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M et al (2014) New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med 6:247ra102. https://doi.org/10.1126/scitranslmed.3008705 CrossRefPubMedPubMedCentral

12.

Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F et al (2011) A research Agenda to underpin malaria eradication. PLoS Med. 8. https://doi.org/10.1371/journal.pmed.1000406

13.

Hoffman SL, Subramanian GM, Collins FH, Venter JC (2002) Plasmodium, human and Anopheles genomics and malaria. Nature 415:702–709. https://doi.org/10.1038/415702a CrossRefPubMed

14.

Ames SK, Hysom DA, Gardner SN, Lloyd GS, Gokhale MB, Allen JE (2013) Scalable metagenomic taxonomy classification using a reference genome database. Bioinformatics 29:2253–2260. https://doi.org/10.1093/bioinformatics/btt389 CrossRefPubMedPubMedCentral

15.

Rutgers T, Gordon D, Gathoye AM, Hollingdale M, Hockmeyer W, Rosenberg M et al (1988) Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum. Bio/Technology 6:1065–1070. https://doi.org/10.1038/nbt0988-1065 CrossRef

16.

Gosling R, von Seidlein L (2016) The future of the RTS,S/AS01 malaria vaccine: an alternative development plan. PLoS Med 13:e1001994. https://doi.org/10.1371/journal.pmed.1001994 CrossRefPubMedPubMedCentral

17.

Phillips MA, Burrows JN, Manyando C, Van Huijsduijnen RH, Van Voorhis WC, Wells TNC (2017) Malaria. Nat Rev Dis Prim 3:17050. https://doi.org/10.1038/nrdp.2017.50 CrossRefPubMed

18.

Draper SJ, Higgins MK (2018) A new site of attack for a malaria vaccine. Nat Med 24:382–383. https://doi.org/10.1038/nm.4533 CrossRefPubMed

19.

D’Alessandro HTU, Sorgho H, Valea I (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45. https://doi.org/10.1016/S0140-6736(15)60721-8 CrossRef

20.

Sack B, Kappe SHI, Sather DN (2017) Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection. Expert Rev Vaccines 16:403–414. https://doi.org/10.1080/14760584.2017.1295853 CrossRefPubMed

21.

Tan J, Sack BK, Oyen D, Zenklusen I, Piccoli L, Barbieri S et al (2018) A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat Med 24:401–407. https://doi.org/10.1038/nm.4513 CrossRefPubMedPubMedCentral

22.

Kisalu NK, Idris AH, Weidle C, Flores-Garcia Y, Flynn BJ, Sack BK et al (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 24:408–416. https://doi.org/10.1038/nm.4512 CrossRefPubMedPubMedCentral

23.

Kariu T, Ishino T, Yano K, Chinzei Y, Yuda M (2006) CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol 59:1369–1379. https://doi.org/10.1111/j.1365-2958.2005.05024.x CrossRefPubMed

24.

Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O et al (2014) Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect Immun 82:1277–1286. https://doi.org/10.1128/IAI.01187-13 CrossRefPubMedPubMedCentral

25.

O’Hara GA, Duncan CJA, Ewer KJ, Collins KA, Elias SC, Halstead FD et al (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205:772–781. https://doi.org/10.1093/infdis/jir850 CrossRefPubMedPubMedCentral

26.

Ewer KJ, O’Hara GA, Duncan CJA, Collins KA, Sheehy SH, Reyes-Sandoval A et al (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4:2836. https://doi.org/10.1038/ncomms3836 CrossRefPubMedPubMedCentral

27.

Vasconcelos JR, Dominguez MR, Araújo AF, Ersching J, Tararam CA, Bruna-Romero O et al (2012) Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol 3:358. https://doi.org/10.3389/fimmu.2012.00358 CrossRefPubMedPubMedCentral

28.

Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C et al (2013) DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8:e55571. https://doi.org/10.1371/journal.pone.0055571 CrossRefPubMedPubMedCentral

29.

de Camargo TM, de Freitas EO, Gimenez AM, Lima LC, de Almeida Caramico K, Françoso KS et al (2018) Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge. Sci Rep 8:1118. https://doi.org/10.1038/s41598-017-19063-6 CrossRefPubMedPubMedCentral

30.

Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D et al (2016) Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01 _B with chimpanzee adenovirus 63 and modified vaccinia Ankara vectored vaccines expressing ME-TRAP. J Infect Dis 214:772–781. https://doi.org/10.1093/infdis/jiw244 CrossRefPubMedPubMedCentral

31.

Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ et al (2017) Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight 2:e89154. https://doi.org/10.1172/jci.insight.89154 CrossRefPubMedPubMedCentral

32.

Clyde DF, McCarthy VC, Miller RM, Hornick RB (1973) Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266:398–403CrossRefPubMed

33.

Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME et al (2017) Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A 114:2711–2716. https://doi.org/10.1073/pnas.1615324114 CrossRefPubMedPubMedCentral

34.

Mordmüller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A et al (2017) Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542:445–449. https://doi.org/10.1038/nature21060 CrossRefPubMed

35.

Mikolajczak SA, Lakshmanan V, Fishbaugher M, Camargo N, Harupa A, Kaushansky A et al (2014) A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 22:1707–1715. https://doi.org/10.1038/mt.2014.85 CrossRefPubMedPubMedCentral

36.

Coelho CH, Yai J, Doritchamou A, Zaidi I, Duffy PE (2017) Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium. npj Vaccines 2:34. https://doi.org/10.1038/s41541-017-0035-3 CrossRefPubMedPubMedCentral

37.

Cohen S, McGregor IA, Carrington S (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192:733–737. https://doi.org/10.1038/192733a0 CrossRefPubMed

38.

Satchwell TJ (2016) Erythrocyte invasion receptors for Plasmodium falciparum: new and old. Transfus Med 26:77–88. https://doi.org/10.1111/tme.12280 CrossRefPubMed

39.

Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL et al (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2:601. https://doi.org/10.1038/ncomms1615 CrossRefPubMedPubMedCentral

40.

Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, Bartholdson SJ et al (2015) A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 17:130–139. https://doi.org/10.1016/j.chom.2014.11.017 CrossRefPubMedPubMedCentral

41.

Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F et al (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2:96381CrossRefPubMed

42.

Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE et al (2014) Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 515:427–430. https://doi.org/10.1038/nature13715 CrossRefPubMedPubMedCentral

43.

Srinivasan P, Christian Baldeviano G, Miura K, Diouf A, Ventocilla JA, Leiva KP et al (2017) A malaria vaccine protects aotus monkeys against virulent Plasmodium falciparum infection. npj Vaccines 2:14. https://doi.org/10.1038/s41541-017-0015-7 CrossRefPubMedPubMedCentral

44.

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK et al (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365:1004–1013. https://doi.org/10.1056/NEJMoa1008115 CrossRefPubMedPubMedCentral

45.

Raj DK, Nixon CP, Nixon CE, Dvorin JD, DiPetrillo CG, Pond-Tor S et al (2014) Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection. Science 344:871–877. https://doi.org/10.1126/science.1254417 CrossRefPubMedPubMedCentral

46.

Healer J, Cowman AF, Kaslow DC, Birkett AJ (2017) Vaccines to accelerate malaria elimination and eventual eradication. Cold Spring Harb Perspect Med 7:a025627. https://doi.org/10.1101/cshperspect.a025627 CrossRefPubMed

47.

Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER et al (2016) Adjuvant and carrier protein- dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. https://doi.org/10.1038/srep40312

48.

MacDonald NJ, Nguyen V, Shimp R, Reiter K, Herrera R, Burkhardt M et al (2016) Structural and immunological characterization of recombinant 6-cysteine domains of the Plasmodium falciparum sexual stage protein Pfs230. J Biol Chem 291:19913–19922. https://doi.org/10.1074/jbc.M116.732305 CrossRefPubMedPubMedCentral

49.

Molina-Cruz A, Garver LS, Alabaster A, Bangiolo L, Haile A, Winikor J et al (2013) The human malaria parasite Pfs47 gene mediates evasion of the mosquito immune system. Science 340(80):984–987. https://doi.org/10.1126/science.1235264 CrossRefPubMed

50.

Molina-Cruz A, Canepa GE, Kamath N, Pavlovic NV, Mu J, Ramphul UN et al (2015) Plasmodium evasion of mosquito immunity and global malaria transmission: the lock-and-key theory. Proc Natl Acad Sci 112:15178–15183. https://doi.org/10.1073/pnas.1520426112 CrossRefPubMed

51.

Caignard G, Eva MM, Van Bruggen R, Eveleigh R, Bourque G, Malo D et al (2014) Mouse ENU mutagenesis to understand immunity to infection: methods, selected examples, and perspectives. Genes (Basel) 5:887–925. https://doi.org/10.3390/genes5040887 CrossRefPubMedCentral

52.

Montoya FG, Baños R, Meroño JE, Manzano-Agugliaro F (2016) The research of water use in Spain. J Clean Prod 112:4719–4732. https://doi.org/10.1016/j.jclepro.2015.06.042 CrossRef

53.

Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW et al (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419:498–511. https://doi.org/10.1038/nature01097 CrossRefPubMed

54.

Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD et al (2002) A proteomic view of the Plasmodium falciparum life cycle. Nature 419:520–526. https://doi.org/10.1038/nature01107 CrossRefPubMed

Titel: Genetic approach towards a vaccine against malaria
verfasst von: Jose Antonio Garrido-Cardenas
Concepción Mesa-Valle
Francisco Manzano-Agugliaro
Publikationsdatum: 28.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2018
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3313-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Evaluation of IVD 3.0 Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium tuberculosis and nontuberculous mycobacteria and its use in routine diagnostics

Etiologies, risk factors, and outcomes of bacterial cholangitis after living donor liver transplantation

Correction to: Antimicrobial-coated sutures to decrease surgical site infections: a systematic review and meta-analysis

Campylobacter jejuni virulence genes and immune-inflammatory biomarkers association with growth impairment in children from Northeastern Brazil

Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series